Exosome drug delivery carrier and application thereof

By using exosome scaffolds modified with specific peptides, the cargo is efficiently enriched and loaded into exosomes, solving the problems of high difficulty in preparing exosome drug delivery vehicles and limited application range in the prior art, and achieving efficient drug delivery Effect.

CN119055797APending Publication Date: 2024-12-03苏州唯思尔康科技有限公司

Patent Information

Application Number
CN202411554331.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-04
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the prior art, the preparation of exosome drug delivery vehicles is difficult, and the length of the scaffold proteins is limited in the application range of the carrier, and it has a great impact on the structure and function of the cargo.

Method used

Using exosomes modified by polypeptides or fusion polypeptides or fusion proteins formed by polypeptides and linkers, using polypeptides with specific amino acid sequences and modifications as exosome scaffolds, the cargo is enriched and loaded into exosomes and through exocrine The body is delivered to the cells.

Benefits of technology

It achieves drug delivery efficiency and enrichment efficiency comparable to full-length exosome scaffold proteins, reduces the difficulty of preparation, is suitable for biological macromolecules with longer sequence lengths, and expands the application range of drug delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055797A_ABST
    Figure CN119055797A_ABST
Patent Text Reader

Abstract

The invention relates to an exosome drug delivery carrier and application thereof.The drug delivery carrier comprises polypeptide modified exosome, polypeptide comprises a first fragment with n amino acids, the amino acid sequence of the first fragment and the first n amino acid sequences of the N end of RFTN1 protein have 80%-100% identity, the second amino acid of the first fragment is myristica myristate acylation modified glycine, the third amino acid of the first fragment is palmitoylation modified cysteine, n is an integer between 6 and 50, the exosome comprises the polypeptide modified exosome or the fusion polypeptide formed by the polypeptide and the connexon or the exosome modified by the fusion protein, and the exosome has high cargo loading and delivery efficiency, and can be used for preparing the exosome. The method has the advantages of simple operation, low preparation difficulty, small influence on cargo structures and functions and wide cargo application range, is especially suitable for biological macromolecular cargoes with longer sequence length, and provides more and better choices for efficient delivery of cargoes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of molecular biology, and specifically relates to an exosome drug delivery carrier and an application thereof. Background Art

[0002] Exosomes are membrane vesicle structures secreted by cells and are important mediators of intercellular communication. As a natural nanoparticle, exosomes have great potential as a drug delivery platform. Compared with some traditional drug delivery methods, exosomes from different cell sources have different tissue and organ targeting, showing the potential of precision medicine. Compared with synthetic lipid nanoparticles, exosomes have lower immunogenicity and better biosafety.

[0003] How to efficiently enrich and load functional cargo into exosomes is the main technical bottleneck in the field of exosome drug delivery. The main technical solutions in the current field need to be implemented with the help of proteins that are highly enriched in exosomes. Such proteins are also called scaffold proteins. Representative scaffold proteins include the exosome scaffold protein PTGFRN protein disclosed in US Patent Document US20200222556A1. Through cell-level engineering transformation, functional drugs are fused with PTGFRN to form a fusion protein, and the functional drugs are enriched in exosomes through overexpression of the fusion protein.

[0004] Scaffold proteins are usually hundreds of amino acids long, for example, the length of PTGFRN protein is 879 amino acids. Since the length of the genome that can be packaged by the vector is limited, the longer the scaffold protein means the shorter the length of the cargo that can be delivered. At the same time, the longer the scaffold protein is, the more difficult it is to construct the expression vector and express the fusion protein, and the higher the difficulty and cost of preparation. In addition, the complex folding conformation of the scaffold protein easily affects the folding conformation and function of the functional cargo. Therefore, the scaffold proteins commonly used in the field currently have great limitations in application. Summary of the invention

[0005] The problem to be solved by the present invention is to develop a new exosome-based drug delivery carrier with lower preparation difficulty and wider application range.

[0006] To solve the above problems, the first aspect of the present invention provides a drug delivery vector, which includes polypeptide-modified exosomes or fusion polypeptides or fusion protein-modified exosomes formed by the polypeptide and a linker, wherein the polypeptide includes a first fragment having n amino acids, the amino acid sequence of the first fragment has 80% to 100% identity with the first n amino acid sequences of the N-terminus (i.e., the nitrogen terminus) of the RFTN1 protein, and the second amino acid of the first fragment is myristoylated glycine, and the third amino acid is palmitoylated cysteine, and n is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or an integer between 16 and 50.

[0007] The present invention uses a newly developed polypeptide as an exosome scaffold to prepare an exosome-based drug delivery carrier, and enriches and loads the cargo into the exosome through an overexpressed polypeptide or a fusion polypeptide or fusion protein containing the polypeptide, and realizes the function of delivering the cargo to the cell through the exosome. Because the length of the polypeptide is shorter, the difficulty of polypeptide modification of exosomes is significantly reduced compared to scaffold protein modification. Because the length of the polypeptide is shorter, the drug delivery carrier of the present invention is particularly suitable for biomacromolecule cargoes with longer sequence lengths.

[0008] In some embodiments of the present invention, the amino acid sequence of the first fragment has 80% identity, 81% identity, 82% identity, 83% identity, 84% identity, 85% identity, 86% identity, 87% identity, 88% identity, 89% identity, 90% identity, 91% identity, 92% identity, 93% identity, 94% identity, 95% identity, 96% identity, 97% identity, 98% identity, 99% identity or 100% identity with the first n amino acid sequences at the N-terminus of the RFTN1 protein.

[0009] According to a preferred aspect of the present invention, the total length of the polypeptide is 9 to 100 amino acids, for example 9 to 10 amino acids or 11 to 100 amino acids. Preferably, the total length of the polypeptide is 11 to 80 amino acids. Further preferably, the total length of the polypeptide is 11 to 60 amino acids. Still further preferably, the total length of the polypeptide is 11 to 50 amino acids. Still further preferably, the total length of the polypeptide is 11 to 30 amino acids. Specifically, the total length of the polypeptide can be 10 amino acids, 11 amino acids, 12 amino acids, 13 amino acids, 14 amino acids, 15 amino acids, 16 amino acids, 17 amino acids, 18 amino acids, 19 amino acids, 20 amino acids, 21 amino acids, 22 amino acids, 23 amino acids, 24 amino acids, 25 amino acids, 26 amino acids, 27 amino acids, 28 amino acids, 29 amino acids or 30 amino acids, etc.

[0010] In some embodiments of the present invention, the first fragment has 15 or 16 amino acids, and the sequence has 80% to 100% identity with the first 15 or 16 amino acid sequence at the N-terminus of the RFTN1 protein, for example, 80% identity, 81% identity, 82% identity, 83% identity, 84% identity, 85% identity, 86% identity, 87% identity, 88% identity, 89% identity, 90% identity, 91% identity, 92% identity, 93% identity, 94% identity, 95% identity, 96% identity, 97% identity, 98% identity, 99% identity or 100% identity.

[0011] According to a preferred aspect of the present invention, the polypeptide further comprises a second fragment connected to the C-terminus (i.e., carbon terminus) of the first fragment, the second fragment having m amino acids, and its sequence is a fragment of the amino acid sequence of the RFTN1 protein or has 80% to 100% identity with a fragment of the amino acid sequence of the RFTN1 protein, and m is an integer greater than 2.

[0012] As a preferred embodiment, the amino acid sequence of the second fragment has 80% to 100% identity with the 2 to m amino acid sequence starting from the n+1th amino acid at the N-terminus of the RFTN1 protein.

[0013] In some embodiments of the present invention, the amino acid sequence of the polypeptide has 90% to 100% identity with the first 11 to 100 amino acid sequence at the N-terminus of the RFTN1 protein, for example, 90% identity, 91% identity, 92% identity, 93% identity, 94% identity, 95% identity, 96% identity, 97% identity, 98% identity, 99% identity or 100% identity.

[0014] Furthermore, the amino acid sequence of the polypeptide has 90% to 100% identity with the first 11 to 50 amino acid sequences at the N-terminus of the RFTN1 protein, for example, 90% identity, 91% identity, 92% identity, 93% identity, 94% identity, 95% identity, 96% identity, 97% identity, 98% identity, 99% identity or 100% identity.

[0015] Further, the amino acid sequence of the polypeptide has 90% to 100% identity with the first 11 to 30 amino acid sequences at the N-terminus of the RFTN1 protein, for example, 90% identity, 91% identity, 92% identity, 93% identity, 94% identity, 95% identity, 96% identity, 97% identity, 98% identity, 99% identity or 100% identity.

[0016] In the present invention, when referring to RFTN1 protein, it does not specifically refer to or limit to RFTN1 protein of a specific source, and can be RFTN1 protein of any source. Humans and animals (including but not limited to mammals, fish and birds, etc.) all contain RFTN1 protein. The RFTN1 protein contained in humans and other mammals usually has the same first 6 amino acid sequences from the N-terminus or only differs in amino acids at one position.

[0017] As a preferred embodiment of the present invention, the amino acid sequence of the first fragment has 80% to 100% identity with the first n amino acid sequences of the N-terminus of human RFTN1 protein, non-human mammalian RFTN1 protein, fish animal RFTN1 protein or bird animal RFTN1 protein, wherein the non-human mammalian RFTN1 protein, fish animal RFTN1 protein or bird animal RFTN1 protein is preferably selected from RFTN1 proteins whose first 6 amino acids from the N-terminus are the same as the first 6 amino acids from the N-terminus of human RFTN1 protein or are different only in one position. Further preferably, the non-human mammalian RFTN1 protein is preferably selected from RFTN1 proteins whose first 6 amino acids from the N-terminus are the same as the first 6 amino acids from the N-terminus of human RFTN1 protein or are different only in the 1st, 4th, 5th or 6th amino acids. Preferably, the 2nd and 3rd amino acids of RFTN1 protein from the N-terminus are G and C, respectively.

[0018] Further preferably, the amino acid sequence of the first fragment is 80% to 100% identical to the first n amino acid sequences from the N-terminus of human RFTN1 protein (amino acid sequence SEQ ID NO: 16), macaque RFTN1 protein (amino acid sequence SEQ ID NO: 60), porcine RFTN1 protein (amino acid sequence SEQ ID NO: 61), mouse RFTN1 protein (amino acid sequence SEQ ID NO: 62), rat RFTN1 protein (amino acid sequence SEQ ID NO: 63), goat RFTN1 protein (amino acid sequence SEQ ID NO: 64), dog RFTN1 protein (amino acid sequence SEQ ID NO: 65), chicken RFTN1 protein (amino acid sequence SEQ ID NO: 66), fish RFTN1 protein (SEQ ID NO: 67), finches RFTN1 protein (amino acid sequence SEQ ID NO: 68) or other animals. These specific RFTN1 proteins provide the first 6 key amino acids from the N-terminus and at the same time, their second and third positions from the N-terminus are also myristoylated and palmitoylated, respectively.

[0019] In some embodiments of the present invention, the amino acid sequence of said polypeptide or said first fragment is: MGCGLNKLEK (SEQ ID NO: 8), MGCGLNKLEKR (SEQ ID NO: 69), MGCGLNKLEKRD (SEQ ID NO: 70), MGCGLNKLEKRDE (SEQ ID NO: 71), MGCGLNKLEKRDEK (SEQ ID NO: 72), MGCGLNKLEKRDEKR (SEQ ID NO: 15), MGCGLNKLEKRDEKRP (SEQ ID NO:73), MGCGLNKLEKRDEKRPG (SEQ ID NO:74), MGCGLNKLEKRDEKRPN (SEQ ID NO:75), MGCGLNKLEKRDEKRPGNI (SEQ ID NO:76), MGCGLNKLEKRDEKRPGNIY (SEQ ID NO:77), MGCGLNKLEKRDD (SEQ ID NO:78), MGCGLNKLEKRDDK (SEQ ID NO:79), MGCGLNKLEKRDDKR (SEQ ID NO:79) NO:80), MGCGLNKLEKRDDKRP (SEQ ID NO:81), MGCGLNKLEKRDDKRPG (SEQ ID NO:82), MGCGLNKLEKRDDKRPGN (SEQ ID NO:83), MGCGLNKLEKRDDKRPGNI (SEQ ID NO:84), MGCGLNKLEKRDDKRPGNIY (SEQ ID NO:85), MGCSLNKLEK (SEQ ID NO:86), MGCSLNKLEKR (SEQ ID NO:87), MGCSLNKLEKRE (SEQ ID NO:88), MGCSLNKLEKREK (SEQ ID NO:89), MGCSLNKLEKREKR (SEQ ID NO:90), MGCSLNKLEKREKRP (SEQ ID NO:91), MGCSLNKLEKREKRPG (SEQ ID NO:92), MGCSLNKLEKREKRPGN (SEQ ID NO:93), MGCSLNKLEKREKRPGN (SEQ ID NO:93) NO:94), MGCSLNKLEKREKRPGNIY (SEQ ID NO:95), MGCRLNKLEK (SEQ ID NO:96), MGCRLNKLEKR (SEQ ID NO:97), MGCRLNKLEKRD (SEQ ID<h2 style=";text-align:left;direction:ltr">NO:98)、MGCRLNKLEKRDD(SEQ ID NO:99)、MGCRLNKLEKRDDR(SEQ ID NO:100)、MGCRLNKLEKRDDRR(SEQ ID NO:101)、MGCRLNKLEKRDDRRP(SEQ ID NO:102)、MGCRLNKLEKRDDRRPG(SEQ ID NO:103)、MGCRLNKLEKRDDRRPGN(SEQ ID NO:104)、MGCRLNKLEKRDDRRPGNI(SEQ ID NO:105)、MGCRLNKLEKRDDRRPGNIY(SEQ ID NO:106)、MGCGLNKLEKH(SEQ ID NO:107)、MGCGLNKLEKHD(SEQ ID NO:108)、MGCGLNKLEKHDE(SEQ ID NO:109)、MGCGLNKLEKHDEK(SEQ ID NO:110)、MGCGLNKLEKHDEKR(SEQ ID NO:111)、MGCGLNKLEKHDEKRP(SEQ ID NO:112)、MGCGLNKLEKHDEKRPG(SEQ ID NO:113)、MGCGLNKLEKHDEKRPGN(SEQ ID NO:114)、MGCGLNKLEKHDEKRPGNI(SEQ ID NO:115)、MGCGLNKLEKHDEKRPGNIY(SEQ ID NO:116)、MGCGLPKLEK(SEQ ID NO:117)、MGCGLPKLEKQ(SEQ ID NO:118)、MGCGLPKLEKQD(SEQ ID NO:119)、MGCGLPKLEKQDE(SEQ ID NO:120)、MGCGLPKLEKQDEN(SEQ ID NO:121)、MGCGLPKLEKQDENS(SEQ ID NO:122)、MGCGLPKLEKQDENSP(SEQ ID NO:123)、MGCGLPKLEKQDENSPG(SEQ ID NO:124)、MGCGLPKLEKQDENSPGK(SEQ ID NO:125)、MGCGLPKLEKQDENSPGKI(SEQ ID NO:126)、MGCGLPKLEKQDENSPGKIY(SEQ ID NO:127)。<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0020] Preferably, the amino acid sequence of the polypeptide or the first fragment is the first 10, first 11, first 12, first 13, first 14, first 15, first 16, first 17, first 18, first 19 or first 20 amino acids at the N-terminus of any amino acid sequence in SEQ ID NO: 16 and SEQ ID NO: 60 to 68.

[0021] According to another aspect of the present invention, the polypeptide further comprises a second segment connected to one end of the first segment, the second segment having f amino acids, and f amino acids are positively charged amino acids, and f is generally an integer greater than 2. Positively charged amino acids can enable the second segment to interact with negatively charged cell membrane phospholipids to improve membrane affinity. Specific positively charged amino acids can be R, K, H, etc.

[0022] Preferably, at least the first 6 amino acids at the N-terminus of the first fragment are 80%-100% identical to the first 6 amino acids at the N-terminus of the human RFTN1 protein.

[0023] Preferably, the first fragment has 6 to 20 amino acids, and the second fragment has 2 to 20 amino acids.

[0024] Still further preferably, the first fragment has 6 to 10 amino acids, and the second fragment has 2 to 10 amino acids.

[0025] In some preferred embodiments of the present invention, the first 6 amino acid sequences at the N-terminus of the polypeptide are 100% identical to the first 6 amino acid sequences at the N-terminus of the RFTN1 protein, and the amino acid sequence of the polypeptide contains multiple consecutive positively charged amino acids.

[0026] In some embodiments of the present invention, the amino acid sequence of the polypeptide is: MGCGLNKKKK (SEQ ID NO: 128), MGCGLNRRRR (SEQ ID NO: 129), MGCGLNHHHH (SEQ ID NO: 130), MGCGLNKKKKRRRR (SEQ ID NO: 131), MGCGLNRRRRKKKK (SEQ ID NO: 132), MGCGLNKKKKHHHH (SEQ ID NO: 133), MGCGLNKKKKKKKKK (SEQ ID NO: 134), MGCSLNKKKK (SEQ ID NO: 135), MGCSLNRRRR (SEQ ID NO: 136), MGCSLNHHHH (SEQ ID NO: 137), MGCSLNKKKKRRRR (SEQ ID NO: 138), MGCSLNRRRRKKKK (SEQ ID NO: 139), MGCRLNKKKKHHHH (SEQ ID NO: 140). NO:140), MGCRLNKKKKKKKKK (SEQ ID NO:141), MGCRLNKKKK (SEQ ID NO:142), MGCRLNRRRRR (SEQ ID NO:143), MGCRLNHHHHH (SEQ ID NO:144), MGCRLNKKKKRRRR (SEQ ID NO:145), MGCRLNRRRRRKKKK (SEQ ID NO:146), MGCRLNKKKKHHHH (SEQ ID NO:147), MGCRLNKKKKKKKKK (SEQ ID NO:148).

[0027] In the embodiment of the present invention, the linker is a polypeptide linker and / or a protein linker. The polypeptide linker can be a cleavable linker or a flexible linker conventionally used in the art that can connect a protein cargo or a polypeptide cargo to the polypeptide to form a fusion protein. The protein linker can be a linker conventionally used in the art that can form a protein-nucleic acid complex with a nucleic acid, a linker that can bind to a small molecule compound, etc.

[0028] A second aspect of the present invention provides a cargo-loaded exosome, wherein the cargo includes a pharmaceutically active molecule, and the cargo-loaded exosome includes the above-mentioned drug delivery carrier and the pharmaceutically active molecule, wherein the pharmaceutically active molecule is connected to the polypeptide, or the pharmaceutically active molecule is connected to a fusion polypeptide or fusion protein formed by the polypeptide and a linker.

[0029] The pharmaceutical active molecules of the present invention include active molecules of preventive drugs, active molecules of therapeutic drugs and active molecules of diagnostic drugs.

[0030] In an embodiment of the present invention, the pharmaceutically active molecule includes one or more of protein molecules and fragments thereof, polypeptide molecules and fragments thereof, nucleic acids and fragments thereof, or small molecule compounds.

[0031] In the present invention, the connection between the pharmaceutically active molecule and the polypeptide or between the pharmaceutically active molecule and the linker can utilize connection technologies such as gene fusion, chemical synthesis, enzyme catalytic connection, self-assembly into a complex, click chemistry, protein engineering, nanotechnology, etc.

[0032] In an embodiment of the present invention, the linker is a polypeptide linker and / or a protein linker. For example, the polypeptide linker can be a cleavable linker or a flexible linker conventionally used in the art that can connect a protein cargo or a polypeptide cargo to the polypeptide to form a fusion protein. For another example, the protein linker can be a linker conventionally used in the art that can form a protein-nucleic acid complex with a nucleic acid, a linker that can bind to a small molecule compound, etc.

[0033] In some embodiments of the present invention, the polypeptide and protein cargo or polypeptide cargo form a fusion polypeptide or fusion protein to modify the exosomes, and the protein cargo or polypeptide cargo is enriched in the exosomes by overexpressing the fusion polypeptide and fusion protein.

[0034] In other embodiments of the present invention, the polypeptide and the linker form a fusion polypeptide or fusion protein to modify the exosomes, the nucleic acid cargo or small molecule compound cargo is bound to the linker, and the nucleic acid cargo or small molecule compound cargo bound thereto is enriched into the exosomes by overexpressing the fusion polypeptide or fusion protein.

[0035] The combination of nucleic acid cargo or small molecule compound cargo and fusion polypeptide or fusion protein is achieved by conventional technical means in the art, for example, the affinity adsorption between the small molecule compound cargo and the linker can be used to connect the small molecule compound to the fusion polypeptide or fusion protein. For example, when sgRNA needs to be delivered, Cas9 protein can be used as a protein linker, and the Cas9 protein can be fused to the N-terminus or C-terminus of the polypeptide as a scaffold to form a fusion protein modified exosome, and sgRNA can form an RNP complex with Cas9 protein, thereby loading sgRNA into exosomes for delivery. For another example, when siRNA needs to be delivered, AGO2 protein can be used as a protein linker, and AGO2 protein can be fused to the N-terminus or C-terminus of the polypeptide as a scaffold to form a fusion protein modified exosome, and siRNA can form an RNP complex with AGO2 protein, thereby loading siRNA into exosomes for delivery.

[0036] In the embodiments of the present invention, the protein molecules include but are not limited to various therapeutic proteins, immunogenic proteins or functional proteins (such as proteins used for gene editing, reporter gene proteins), enzyme proteins, etc.

[0037] In the embodiments of the present invention, the polypeptide molecules include but are not limited to various therapeutic polypeptides, targeting polypeptides or partial polypeptide fragments of the above proteins, such as antibodies, cytokines, anti-inflammatory proteins or polypeptides, serum albumin, lectins, coagulation factors, etc.

[0038] In the embodiments of the present invention, the nucleic acid includes but is not limited to various functional nucleic acid molecules, such as DNA or mRNA molecules encoding proteins or polypeptides, RNA molecules with regulatory functions such as miRNA, antisense oligonucleotides ASO or siRNA, sgRNA of CRISPR system, and even plasmid DNA.

[0039] In an embodiment of the present invention, the pharmaceutically active molecule is a cytokine receptor protein, a pro-inflammatory cytokine, a protein or RNA for gene editing.

[0040] In the embodiments of the present invention, the proteins used for gene editing include various proteins used in gene editing technology / engineering, including but not limited to various recombinases that can promote the recombination or rearrangement of specific sequences between DNA molecules and gene editing system-related proteins (i.e., proteins used in various gene editing systems). Known common gene editing-related proteins include but are not limited to Cre recombinase, Dre recombinase, Flp recombinase, RadA protein, RAD51 protein, RecA protein, Cas protein, transposon protein, zinc finger protein and TALE protein.

[0041] In some embodiments of the present invention, the drug active molecule is Cre recombinase, Dre recombinase, Flp recombinase, cGAS, Cas protein, 4-1BBL, TMPRSS2, CD20, CD133, CCR4, CCR7, CCR8, CXCR4, CXCR5, GIPR, GPRC5D, NaPi2b, sgRNA, ASO, microRNA, mRNA or siRNA.

[0042] In some embodiments of the present invention, the pharmaceutically active molecule is a protein molecule and a fragment thereof or a polypeptide molecule and a fragment thereof, and the pharmaceutically active molecule is connected to the N-terminus and / or C-terminus of the polypeptide directly or through a polypeptide linker.

[0043] In other embodiments of the present invention, the pharmaceutically active molecule is a nucleic acid and a fragment thereof or a small molecule compound, the cargo-loaded exosomes include exosomes modified with a fusion polypeptide or fusion protein formed by the polypeptide and a linker, and the pharmaceutically active molecule and the linker combine to form a complex.

[0044] The third aspect of the present invention provides a pharmaceutical composition, which includes the above-mentioned drug delivery vector or the above-mentioned cargo-loaded exosomes, and the pharmaceutical composition may selectively include pharmaceutically acceptable excipients.

[0045] In the embodiments of the present invention, specific excipients can be selected according to the intended mode of administration and therapeutic application. The pharmaceutically acceptable excipients include but are not limited to pharmaceutically, nutritionally or physiologically acceptable carriers.

[0046] Furthermore, the pharmaceutical composition is in the form of tablets, granules, pills, capsules, emulsions, pastes, gels, suspensions, solutions, powders, transdermal patches, sprays, suppositories or implants.

[0047] The fourth aspect of the present invention also provides a method for preparing the above-mentioned drug delivery vector, wherein the drug delivery vector is separated from the cell culture fluid of a recombinant cell, wherein the recombinant cell contains the polypeptide or a fusion polypeptide or fusion protein formed by the polypeptide and a linker.

[0048] Furthermore, the preparation method includes the step of transfecting a host cell with a recombinant expression vector to obtain the recombinant cell, wherein the recombinant expression vector is a plasmid vector containing a gene encoding the polypeptide or a plasmid vector containing both the polypeptide and the linker encoding genes, and optionally contains the linker encoding gene.

[0049] In the embodiments of the present invention, the recombinant cells involved in the preparation method are obtained by transfecting host cells with recombinant expression vectors.

[0050] In some embodiments of the present invention, the cargo is a protein cargo or a polypeptide cargo, and the polypeptide coding gene in the recombinant expression vector is directly or indirectly connected to the cargo coding gene through a gene encoding a linker, thereby fusing the polypeptide with the cargo. Whether a linker is needed can be determined based on the structure, function, stability, etc. of the polypeptide and the effective substance.

[0051] In other embodiments of the present invention, the cargo is a nucleic acid cargo (e.g., RNA), and the nucleic acid cargo can exist in the form of a protein-nucleic acid complex with a linker, and the linker is connected to the polypeptide to indirectly connect the nucleic acid to the polypeptide. For example, a fusion protein is formed by a polypeptide and a protein linker, and at the same time, the protein linker and the nucleic acid cargo form a complex through non-covalent interactions. There is no particular limitation on whether the coding gene of the cargo is connected to the coding gene of the polypeptide or the linker, as long as it can be expressed in a recombinant cell.

[0052] In other embodiments of the present invention, when the cargo is a nucleic acid cargo or a small molecule compound cargo, the prepared exosomes overexpressing a fusion polypeptide or fusion protein formed by the polypeptide and the linker can be directly mixed with the cargo, and the cargo and the linker can be combined to form a complex.

[0053] In the embodiments of the present invention, the expression vector used may be an expression vector conventionally used in the art, including a viral plasmid vector and a eukaryotic expression plasmid vector, and a viral plasmid vector is preferably used.

[0054] In an embodiment of the present invention, a recombinant expression vector is used to introduce an exogenous nucleic acid fragment encoding a "polypeptide" or a fusion polypeptide or fusion protein of a "polypeptide-linker" or a fusion protein of a "polypeptide-cargo" or a fusion protein of a "polypeptide-linker-cargo" or a nucleic acid-protein complex into a cell for expression.

[0055] In the embodiment of the present invention, the expression vector used by the recombinant expression vector is a pAAVS1 plasmid, a pIRES plasmid, or a pLENTI plasmid.

[0056] In the embodiment of the present invention, the host cell used can be any suitable cell type, including mammalian cells, insect cells, preferably mammalian cells, such as HEK293 cells, CHO cells, or SF9 cells.

[0057] In an embodiment of the present invention, the culture medium used to culture the recombinant cells is a serum-free culture medium.

[0058] In an embodiment of the present invention, exosome separation and purification methods known in the art can be used, including but not limited to ultracentrifugation, density gradient centrifugation, size exclusion chromatography, affinity chromatography, adsorption chromatography, bonded phase chromatography, filtration, polymer-based precipitation technology, immunoseparation technology, or sieving separation.

[0059] According to some embodiments of the present invention, the separation is performed by centrifugation, and the cell culture fluid of the recombinant cells is first centrifuged at a centrifugal force of less than 1000g to collect the supernatant, and then the supernatant is centrifuged at a centrifugal force of 100000g~200000g to collect the precipitate, which is the drug delivery vector or the cargo-loaded exosomes.

[0060] Furthermore, the cell culture fluid of the recombinant cells is first centrifuged at a centrifugal force of 200g~500g, the supernatant is collected, and then the supernatant is centrifuged at a centrifugal force of 120000g~150000g to collect the precipitate, which is the cargo-loaded exosomes.

[0061] The present invention fifthly provides a kit, which comprises the above-mentioned drug delivery vector, the above-mentioned cargo-loaded exosomes, or the above-mentioned pharmaceutical composition.

[0062] A sixth aspect of the present invention provides a method for diagnosing, preventing or treating a disease, the method comprising administering the cargo-loaded exosomes or the pharmaceutical composition to a subject.

[0063] In the embodiment of the present invention, it is preferred to determine the specific disease that the cargo-loaded exosomes correspond to detect, prevent or treat based on the active pharmaceutical molecules loaded on the exosomes, including but not limited to various tumor diseases or infectious diseases.

[0064] Due to the adoption of the above technical solution, the present invention has the following advantages compared with the prior art: The present invention has developed a new exosome-based drug delivery carrier, which uses a polypeptide or a fusion polypeptide or fusion protein formed by the polypeptide and a linker as an exosome scaffold to enrich the cargo into the exosome, and its enrichment loading efficiency and delivery efficiency of the cargo can reach a level comparable to that of the exosome modified with the full-length exosome scaffold protein. Since the length of the polypeptide used in the present invention can be much smaller than the length of the exosome scaffold protein, the engineering modification difficulty of the exosome is lower, so the preparation difficulty of the drug delivery carrier of the present invention or the exosome loaded with cargo is lower. Compared with the scaffold protein, the polypeptide has less effect on the structure and function of the cargo, and has a wider range of application for the cargo. The drug delivery carrier of the present invention is particularly suitable for biomacromolecule cargoes with longer sequence lengths, providing more and better choices for the efficient delivery of cargoes. BRIEF DESCRIPTION OF THE DRAWINGS

[0065] Figure 1 This is a particle size distribution diagram of the exosomes loaded with Cre recombinant protease prepared in Example 1; Figure 2 This is a particle size distribution diagram of the exosomes loaded with Cre recombinant protease prepared in Example 2; Figure 3This is the particle size distribution diagram of the exosomes loaded with Cre recombinant protease prepared in Comparative Example 1; Figure 4 This is the particle size distribution diagram of the exosomes loaded with Cre recombinant protease prepared in Comparative Example 2; Figure 5 This is a particle size distribution diagram of exosomes loaded with Cas9 gene editing protein prepared in Example 3; Figure 6 This is a particle size distribution diagram of exosomes loaded with Cas9 gene editing protein prepared in Example 4; Figure 7 This is a particle size distribution diagram of exosomes loaded with Cas9 gene editing protein prepared in Comparative Example 3; Figure 8 This is a particle size distribution diagram of the exosomes loaded with cGAS pro-inflammatory protein prepared in Example 5; Fig. 9 This is a particle size distribution diagram of the exosomes loaded with cGAS pro-inflammatory protein prepared in Example 6; Fig.10 This is a particle size distribution diagram of exosomes loaded with cGAS pro-inflammatory protein prepared in Comparative Example 4; Fig.11 This is the particle size distribution diagram of the TMPRSS2-loaded exosomes prepared in Example 7; Fig.12 This is the particle size distribution diagram of the exosomes loaded with TMPRSS2 prepared in Comparative Example 5; Fig.13 This is a transmission electron microscopy image of the exosomes loaded with Cre recombinant protease prepared in Example 1; Fig.14 This is a transmission electron microscopy image of the exosomes loaded with Cre recombinant protease prepared in Example 2; Fig.15 This is a transmission electron microscopy image of exosomes loaded with Cre recombinant protease prepared in Comparative Example 1; Fig.16 This is a transmission electron microscopy image of exosomes loaded with Cre recombinant protease prepared in Comparative Example 2; Fig.17 This is a transmission electron micrograph of exosomes loaded with Cas9 gene editing protein prepared in Example 3; Fig.18 This is a transmission electron micrograph of exosomes loaded with Cas9 gene editing protein prepared in Example 4; Fig.19 This is a transmission electron micrograph of exosomes loaded with Cas9 gene editing protein prepared in Comparative Example 3; Fig. 20 This is a transmission electron micrograph of the exosomes loaded with cGAS pro-inflammatory protein prepared in Example 5; Fig.21This is a transmission electron micrograph of the exosomes loaded with cGAS pro-inflammatory protein prepared in Example 6; Fig. 22 This is a transmission electron micrograph of exosomes loaded with cGAS pro-inflammatory protein prepared in Comparative Example 4; Fig.23 This is a transmission electron microscopy image of the TMPRSS2-loaded exosomes prepared in Example 7; Fig.24 This is a transmission electron microscopy image of the exosomes loaded with TMPRSS2 prepared in Comparative Example 5; Fig.25 The immunoblotting results of the exosomes loaded with Cre recombinant protease prepared in Example 1, Example 2 and Comparative Example 1 are shown; Fig.26 A comparison chart of cargo delivery effects of exosomes loaded with Cre recombinant protease prepared in Example 1, Example 2, Comparative Example 1 and Comparative Example 2; Fig. 27 This is a diagram showing the results of immunoblotting of exosomes loaded with Cas9 gene editing protein prepared in Example 3, Example 4 and Comparative Example 3; Fig.28 A comparison of cargo delivery effects of exosomes loaded with Cas9 gene editing protein prepared in Example 3, Example 4 and Comparative Example 3; Fig.29 The immunoblotting test results of the exosomes loaded with cGAS pro-inflammatory protein prepared in Example 5, Example 6 and Comparative Example 4 are shown; Fig.30 A comparison chart of cargo delivery effects of exosomes loaded with cGAS pro-inflammatory protein prepared in Example 5, Example 6 and Comparative Example 4; Fig.31 This is a graph showing the results of immunoblotting of exosomes loaded with TMPRSS2 prepared in Example 7 and Comparative Example 5. DETAILED DESCRIPTION

[0066] As a natural nanoparticle, exosomes have great potential as a drug delivery platform. How to efficiently load functional cargo on exosomes is the main technical bottleneck in the field of exosomes. Current research is mainly focused on the development of exosome scaffold proteins. Exosomes modified with scaffold proteins are obtained through cell-level engineering transformation. The scaffold protein is directly fused with the cargo or the scaffold protein is fused with the linker, and the linker is combined with the cargo to load the cargo into the exosome. Although some scaffold proteins can be highly enriched in exosomes to achieve a high cargo loading efficiency, the length of the scaffold protein reaches hundreds of amino acids, which makes cell engineering transformation difficult and reduces the expression efficiency of the protein. In addition, since the length of the genome that can be packaged by the expression plasmid vector is limited, the longer the scaffold protein means the shorter the length of the cargo that can be delivered, which limits the application scope of exosome-based drug delivery vectors.

[0067] Through systematic research, the present invention discovered a new scaffold protein RFTN1 protein. After further research, the unexpectedly obtained polypeptide and its mutants can play the function of exosome scaffold protein under the specific amino acid modification conditions that the second amino acid is myristoylated glycine and the third amino acid is palmitoylated cysteine.

[0068] In some embodiments of the present invention, polypeptides whose amino acid sequences are consistent with the first 5, first 10, first 15, first 20, first 30, first 50, first 80, and first 100 amino acid sequences at the N-terminus of RFTN1 protein are selected, and the second amino acid of these polypeptides is modified by myristoylation and the third amino acid is modified by palmitoylation. Among them, the polypeptides whose amino acid sequences are consistent with the first 5 amino acid sequences at the N-terminus of RFTN1 protein can already load a small amount of Cre recombinant protease into exosomes; the polypeptides whose amino acid sequences are consistent with the first 10 amino acid sequences at the N-terminus of RFTN1 protein can load more Cre recombinant protease into exosomes and achieve efficient cell delivery, but the effect is slightly worse than that of RFTN1 protein; the polypeptides whose amino acid sequences are consistent with the first 15 amino acid sequences at the N-terminus of RFTN1 protein can already achieve loading efficiency and delivery efficiency comparable to that of RFTN1 protein; the polypeptides whose amino acid sequences are consistent with the first 20, first 30, first 50, first 80, and first 100 amino acid sequences at the N-terminus of RFTN1 protein have loading efficiency and delivery efficiency comparable to that of RFTN1 protein.

[0069] In another embodiment of the present invention, a mutant of the above-mentioned polypeptide is used as a scaffold protein. When ensuring that at least the first 6 amino acid sequences of the N-terminus of the above-mentioned polypeptide have more than 80% identity with the first 6 amino acid sequences of the N-terminus of the RFTN1 protein and the second amino acid starting from the N-terminus of the polypeptide is myristoylated glycine and the third amino acid starting from the N-terminus is palmitoylated cysteine, the mutated polypeptide still has the function of enriching the cargo into exosomes and delivering the cargo to cells through exosomes, but different polypeptide mutants have different enrichment efficiencies in exosomes. In practical applications, appropriate polypeptide mutants can be selected as needed to change the enrichment efficiency of the cargo in exosomes. For example, it has been found that, under the premise of ensuring that at least the first 6 amino acid sequences of the N-terminus of the first fragment have 100% identity with the first 6 amino acid sequences of the N-terminus of the RFTN1 protein, and the second amino acid starting from the N-terminus of the polypeptide is myristoylated glycine and the third amino acid starting from the N-terminus is palmitoylated cysteine, partially or completely mutating the subsequent amino acids to positively charged amino acids can improve the affinity of the membrane and further improve the enrichment efficiency of the cargo in exosomes.

[0070] Unless otherwise specified or contradictory to the context, the terms or expressions used herein should be read in conjunction with the overall content of this article and as understood by those of ordinary skill in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art.

[0071] "Exosomes" refer to cell-derived extracellular vesicles (EVs) with a diameter of 20-300 nm, which include a membrane that encloses the internal space and has a phospholipid bilayer structure. Exosomes can mediate the intercellular transfer of intracellular substances.

[0072] “Loading” refers to the attachment and enrichment of cargo into exosomes, including various forms such as cargo in the lumen of exosomes, on the membrane of exosomes, or attached to the outside of the membrane of exosomes.

[0073] "Scaffold" refers to a connector used to connect cargo to exosomes, which is used to anchor any cargo of interest to exosomes, and its type can be a protein, called a "scaffold protein", or a polypeptide developed by the present invention.

[0074] "Cargo" mainly refers to "pharmaceutically active molecules", i.e., proteins and fragments thereof, polypeptides and fragments thereof, nucleic acids and fragments thereof, or small molecule compounds of any functional interest (e.g., preventive, therapeutic, diagnostic, etc.). "Cargo" is also often referred to as "functional cargo" or "effective substance".

[0075] "Small molecule compound" refers to a compound with a molecular size less than 1000 molecular weight, including conventional organic compounds and inorganic compounds.

[0076] "Polypeptide" and "oligopeptide" are defined according to the length of the peptide chain. Those with a length of 10 to 100 amino acids are called "polypeptides", and those with a length of less than 10 amino acids are called "oligopeptides".

[0077] "Recombinase" is a class of enzymes that can promote the recombination or rearrangement of specific sequences between DNA molecules. Common recombinases can be loaded and delivered using the method of the present invention. Common recombinases include but are not limited to Cre recombinase, Dre recombinase, Flp recombinase, RadA protein, RAD51 protein and RecA protein.

[0078] "Gene editing proteins" are a class of proteins used in gene editing systems. Common gene editing proteins include Cas proteins (such as Cas9, Cas12, Cas13, Cas2, Cas3, Cas10, Cas14, Cas12f, CasX, CasY or Csm), transposon proteins, zinc finger proteins and TALE proteins.

[0079] "Exogenous nucleic acid fragments" include any gene or fragment thereof of interest, such as a gene or fragment thereof encoding a scaffold protein. Exogenous nucleic acid fragments have a different origin from the host cell, for example, nucleic acid sequences isolated from an organism different from the host cell, i.e., are exogenous nucleic acid fragments relative to the host cell.

[0080] "Expression vector" refers to a nucleic acid molecule that is capable of transporting another nucleic acid molecule to which it is attached. Examples of vectors include, but are not limited to, plasmids, viruses, bacteria, bacteriophages, and insertable DNA fragments. The "plasmid" refers to a circular double-stranded DNA that is capable of accepting exogenous nucleic acid fragments and can replicate in prokaryotic or eukaryotic cells.

[0081] "Promoter" refers to a nucleic acid sequence that can control the transcription of a coding sequence. The promoter sequence includes a specific sequence sufficient for RNA polymerase recognition, binding and transcription initiation. The promoter can affect the transcription of a gene located on the same nucleic acid molecule as itself or a gene located on a different nucleic acid molecule from itself.

[0082] "Host cell" is also called recipient cell, including but not limited to animal cells, plant cells, algae cells, fungal cells, yeast cells, or bacterial cells. Exemplary host cells include human embryonic kidney cells HEK293. It should be understood that the offspring of a single parental cell may not be completely identical to the original parent in morphology or in terms of genome or total DNA complement due to natural, accidental or intentional mutations.

[0083] "Cre recombinase" is a protein encoded by a 1029bp sequence in the genome of bacterial phage P1. It consists of 343 amino acids and has a molecular weight of 3815kD. It is a type I topoisomerase that catalyzes site-specific recombination of DNA between loxP sites and is used for gene insertion and deletion in gene therapy.

[0084] "Cas9 gene editing protein" is a nuclease in the CRISPR-Cas system that can specifically cut DNA molecules.

[0085] The "cGAS pro-inflammatory protein" is a major sensor of cytoplasmic DNA and a pro-inflammatory cytokine that can activate STING, induce type 1 IFN expression and IFN stimulation.

[0086] “4-1BBL” (4-1BB ligand), also known as CD137L, is a type II transmembrane protein that belongs to the TNF superfamily and plays an important role in the activation of immune responses. For example, 4-1BBL transduces co-stimulatory signals to promote CD4 + and CD8 + Proliferation, activation and survival of T cells; signaling through 4-1BBL on monocytes can induce the production of inflammatory cytokines; on macrophages, 4-1BBL binds to TLR4 in cis, enhancing the production of inflammatory cytokines.

[0087] "TMPRSS2" is a type II transmembrane protein whose extracellular domain has protease activity, which can cut and activate viral proteins, thereby facilitating the entry of a variety of viruses into the host, including the spike proteins in SARS-CoV-2, SARS-CoV and MERS-CoV, and the hemagglutinin in influenza A virus. TMPRSS2 is the main target for preventing infection with the new coronavirus.

[0088] The technical solution of the present invention is further described below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments.

[0089] The implementation conditions used in the following examples and comparative examples can be further adjusted according to specific requirements, and the implementation conditions not specified are usually the conditions in conventional experiments. The instruments, raw materials and reagents not specifically specified can be obtained commercially. Example 1

[0090] This embodiment provides an exosome loaded with Cre recombinant protease, and the preparation method thereof is as follows: 1. Construction of expression vector The expression vector used in this example is a pIRES plasmid. The expression cassette is designed as follows: a CMV promoter (sequence shown in SEQ ID NO: 1) is used as the transcription start point, and the N-terminal fusion polypeptide MGCGLNKLEKRDEKR (SEQ ID NO: 3, the second amino acid is myristoylated and the third amino acid is palmitoylated) of the Cre recombinase (sequence shown in SEQ ID NO: 2) is fused. SV40 polyA (sequence shown in SEQ ID NO: 4) is used as the transcription end point.

[0091] The specific steps are as follows: (1) PCR cloning: Use conventional methods in the art to design upstream primers and downstream primers based on the above expression cassette, synthesize upstream primers (sequence as shown in SEQ ID NO: 5), downstream primers (sequence as shown in SEQ ID NO: 6) and template DNA (sequence as shown in SEQ ID NO: 7). In a 0.2mL EP tube, add 25μL DNA polymerase (2×Phanta MaxMaster Mix, Vazyme, P515-01), 2μL upstream primer, 2μL downstream primer, 10g template DNA, add enzyme-free water (RNase-free ddH2O, Vazyme, P071-01-AA) to 50μL, mix well and put into a PCR instrument, and design the amplification program according to the primer annealing temperature.

[0092] (2) Purification of PCR products: Purify the PCR products according to the kit instructions (Vazyme, DC301-01).

[0093] (3) Enzyme digestion: Add 5 μL rCutSmart TM Buffer (BioLabs, 136004s), 0.5μL Pac I enzyme (BioLabs, R0547L), 0.5μL Not I enzyme (BioLabs, R3189L), 2μg PCR purified fragment, 5μg pAAVS1 vector plasmid. Add enzyme-free water (RNase-free ddH2O, Vazyme, P071-01-AA) to 10μL, mix well, and place in a PCR instrument for enzyme digestion at 37℃ for 16h.

[0094] (4) Ligation transformation: In a 0.2 mL EP tube, add 4 μL of the digestion solution obtained in step (3), 1 μL of T4 DNA ligase (Vazyme, N103-01-AA) and 1 μL of T4 DNA ligase buffer (Vazyme, N103-01-AC). After incubating at room temperature for 10 min, take out 5 μL and add it to competent cells (DH5α, Vazyme, C502-03), incubate on ice for 30 min, incubate at 42°C for 90 s, incubate on ice for 2 min, then add 1 mL LB medium (BeyoPure™, 04.05.ST156) and culture in a shaking incubator for 1 h. After culture, centrifuge at 12000g for 1 min, remove the supernatant and keep 100 μL, resuspend and add to the bacterial culture dish (White Shark Biosharp, BS-90-D), then use a disposable plastic coating rod (White Shark Biosharp, BS-PS-A) to spread evenly and store in a 37°C constant temperature incubator for later use.

[0095] 2. Cell Transfection The specific steps are as follows: (1) Prepare cells for transfection EXPI293F cells were inoculated into a 125 mL shake flask at 1.5E+6 / mL with a survival rate of more than 95%, and the total volume of the culture medium was 25 mL. The cells were placed in an 8% CO2 constant temperature shaker for overnight culture, and transfection was started the next day.

[0096] (2) PEI transfection Using TA293 reagent (Zhuhai Kairui Biotechnology Co., Ltd., K2001), taking a volume of 25 mL of cell suspension as an example, the transfection process is as follows: The target plasmid is extracted from the transformed competent cells preserved by the above-mentioned coating culture by conventional technical means in the art, and the constructed expression vector is obtained. Prepare two 15mL centrifuge tubes, add 1.25mL serum-free cell culture medium and 25μg target expression plasmid to one of them, and vortex to mix; add 1.25mL serum-free cell culture medium and 125μLTA293 transfection reagent to the other, and vortex to mix. Transfer all the liquid in the centrifuge tube containing the transfection reagent to the centrifuge tube containing the plasmid and vortex to mix. Incubate at room temperature for 10 minutes to prepare the plasmid-vector complex. Remove the EXPI293F cells from the constant temperature shaker, add the prepared plasmid-vector complex dropwise while shaking, and then return to the CO2 constant temperature shaker for shaking and culture for 72 hours.

[0097] 3. Isolation and purification of exosomes After 72 hours of shaking culture, the cell culture fluid was first centrifuged at 300g, 4°C, for 5 minutes, and the supernatant was collected. The supernatant was then ultracentrifuged at 133900g, 4°C for 1 hour to collect the precipitate. The precipitate (i.e., the isolated exosomes) was resuspended in 100 μL PBS and stored at 4°C for later use. Example 2

[0098] In this example, the polypeptide MGCGLNKLEK (SEQ ID NO: 8, the second amino acid is myristoylated and the third amino acid is palmitoylated) is used as an exosome scaffold, and exosomes loaded with Cre recombinant protease are prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame is replaced with the polypeptide with the amino acid sequence shown in SEQ ID NO: 8, and the upstream primer (sequence shown in SEQ ID NO: 9), the downstream primer (sequence shown in SEQ ID NO: 10) and the template DNA (sequence shown in SEQ ID NO: 11) of the synthetic PCR cloning step are redesigned according to the adjusted expression frame. The rest is referred to Example 1, and finally exosomes loaded with Cre recombinant protease are obtained. Comparative Example 1

[0099] In this comparative example, oligopeptide MGCGL (SEQ ID NO: 12, the second amino acid is myristoylated and the third amino acid is palmitoylated) is used as an exosome scaffold, and exosomes loaded with Cre recombinant protease are prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame is replaced with the oligopeptide with the amino acid sequence shown in SEQ ID NO: 12, and the upstream primer (sequence shown in SEQ ID NO: 13), the downstream primer (sequence shown in SEQ ID NO: 14) and the template DNA (sequence shown in SEQ ID NO: 15) of the synthetic PCR cloning step are redesigned according to the adjusted expression frame. The rest is referred to Example 1, and finally exosomes loaded with Cre recombinant protease are obtained. Comparative Example 2

[0100] In this comparative example, RFTN1 protein (amino acid sequence as shown in SEQ ID NO: 16) was used as the exosome scaffold protein, and exosomes loaded with Cre recombinant protease were prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence as shown in SEQ ID NO: 3 in the expression frame was replaced with the RFTN1 protein with the amino acid sequence as shown in SEQ ID NO: 16, and the upstream primer (sequence as shown in SEQ ID NO: 17), the downstream primer (sequence as shown in SEQ ID NO: 18) and the template DNA (sequence as shown in SEQ ID NO: 19) of the synthetic PCR cloning step were redesigned according to the adjusted expression frame. The rest was referred to Example 1, and finally exosomes loaded with Cre recombinant protease were obtained. Example 3

[0101] This embodiment provides an exosome loaded with Cas9 gene editing protein, using the same polypeptide as in Example 1 as an exosome scaffold, and preparing exosomes loaded with Cas9 gene editing protein with reference to the preparation method of Example 1. The Cre recombinase in the expression frame with the sequence shown in SEQ ID NO: 2 is replaced with the Cas9 gene editing protein with the sequence shown in SEQ ID NO: 20, and the upstream primer (sequence shown in SEQ ID NO: 21), the downstream primer (sequence shown in SEQ ID NO: 22) and the template DNA (sequence shown in SEQ ID NO: 23) of the synthetic PCR cloning step are redesigned according to the adjusted expression frame (the expression frame designed in Example 1), and the rest is referred to Example 1, and finally exosomes loaded with Cas9 gene editing protein are obtained. Example 4

[0102] In this example, the polypeptide MGCGLNKLEK (SEQ ID NO: 8, the second amino acid is myristoylated and the third amino acid is palmitoylated) is used as an exosome scaffold, and exosomes loaded with Cas9 gene editing protein are prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame is replaced with the polypeptide with the amino acid sequence shown in SEQ ID NO: 8, and the Cre recombinase with the sequence shown in SEQ ID NO: 2 is replaced with the Cas9 gene editing protein with the sequence shown in SEQ ID NO: 20. Except for redesigning the upstream primer (sequence shown in SEQ ID NO: 24), the downstream primer (sequence shown in SEQ ID NO: 25) and the template DNA (sequence shown in SEQ ID NO: 26) of the synthetic PCR cloning step according to the adjusted expression frame, the rest is referred to Example 1, and finally exosomes loaded with Cas9 gene editing protein are obtained. Comparative Example 3

[0103] In this comparative example, oligopeptide MGCGL (SEQ ID NO: 12, the second amino acid is myristoylated and the third amino acid is palmitoylated) is used as an exosome scaffold, and exosomes loaded with Cas9 gene editing protein are prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame is replaced with the oligopeptide with the amino acid sequence shown in SEQ ID NO: 12, and the Cre recombinase with the sequence shown in SEQ ID NO: 2 is replaced with the Cas9 gene editing protein with the sequence shown in SEQ ID NO: 20. In addition to redesigning the upstream primer (sequence shown in SEQ ID NO: 27), the downstream primer (sequence shown in SEQ ID NO: 28) and the template DNA (sequence shown in SEQ ID NO: 29) of the synthetic PCR cloning step according to the adjusted expression frame, the rest is referred to Example 1, and finally exosomes loaded with Cas9 gene editing protein are obtained. Example 5

[0104] This example provides an exosome loaded with a cGAS pro-inflammatory protein, and the same polypeptide as in Example 1 is used as an exosome scaffold, and the exosome loaded with the cGAS pro-inflammatory protein is prepared with reference to the preparation method of Example 1. The Cre recombinant protease in the expression frame as shown in SEQ ID NO: 2 is replaced with the cGAS pro-inflammatory protein as shown in SEQ ID NO: 30, and the upstream primer (sequence as shown in SEQ ID NO: 31), the downstream primer (sequence as shown in SEQ ID NO: 32) and the template DNA (sequence as shown in SEQ ID NO: 33) of the synthetic PCR cloning step are redesigned according to the adjusted expression frame (the expression frame designed in Example 1), and the rest is referred to Example 1, and finally the exosome loaded with the cGAS pro-inflammatory protein is obtained. Example 6

[0105] In this example, the polypeptide MGCGLNKLEK (SEQ ID NO: 8, the second amino acid is myristoylated and the third amino acid is palmitoylated) is used as an exosome scaffold, and exosomes loaded with cGAS pro-inflammatory protein are prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame is replaced with the polypeptide with the amino acid sequence shown in SEQ ID NO: 8, and the Cre recombinant protease with the sequence shown in SEQ ID NO: 2 is replaced with the cGAS pro-inflammatory protein with the sequence shown in SEQ ID NO: 30. In addition to redesigning the upstream primer (sequence shown in SEQ ID NO: 34), the downstream primer (sequence shown in SEQ ID NO: 35) and the template DNA (sequence shown in SEQ ID NO: 36) of the synthetic PCR cloning step according to the adjusted expression frame, the rest is referred to Example 1, and finally exosomes loaded with cGAS pro-inflammatory protein are obtained. Comparative Example 4

[0106] In this comparative example, oligopeptide MGCGL (SEQ ID NO: 12, the second amino acid is myristoylated and the third amino acid is palmitoylated) is used as an exosome scaffold, and exosomes loaded with cGAS pro-inflammatory protein are prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame is replaced with the oligopeptide with the amino acid sequence shown in SEQ ID NO: 12, and the Cre recombinant protease with the sequence shown in SEQ ID NO: 2 is replaced with the cGAS pro-inflammatory protein with the sequence shown in SEQ ID NO: 30. In addition to redesigning the upstream primer (sequence shown in SEQ ID NO: 37), the downstream primer (sequence shown in SEQ ID NO: 38) and the template DNA (sequence shown in SEQ ID NO: 39) of the synthetic PCR cloning step according to the adjusted expression frame, the rest is referred to Example 1, and finally exosomes loaded with cGAS pro-inflammatory protein are obtained. Example 7

[0107] This embodiment provides an exosome loaded with TMPRSS2, using the same polypeptide as in Example 1 as an exosome scaffold, and preparing exosome loaded with TMPRSS2 with reference to the preparation method of Example 1. The Cre recombinase in the expression frame as shown in SEQ ID NO: 2 is replaced with TMPRSS2 as shown in SEQ ID NO: 40. Except for redesigning the upstream primer (sequence as shown in SEQ ID NO: 41), the downstream primer (sequence as shown in SEQ ID NO: 42) and the template DNA (sequence as shown in SEQ ID NO: 43) of the synthetic PCR cloning step according to the adjusted expression frame, the rest is referred to Example 1, and finally exosome loaded with TMPRSS2 is obtained. Comparative Example 5

[0108] In this comparative example, oligopeptide MGCGL (SEQ ID NO: 12, the second amino acid is myristoylated and the third amino acid is palmitoylated) is used as an exosome scaffold, and exosomes loaded with TMPRSS2 are prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame is replaced with the oligopeptide with the amino acid sequence shown in SEQ ID NO: 12, and the Cre recombinant protease with the sequence shown in SEQ ID NO: 2 is replaced with the TMPRSS2 with the sequence shown in SEQ ID NO: 40. Except for redesigning the upstream primer (sequence shown in SEQ ID NO: 44), the downstream primer (sequence shown in SEQ ID NO: 45) and the template DNA (sequence shown in SEQ ID NO: 46) of the synthetic PCR cloning step according to the adjusted expression frame, the rest is referred to Example 1, and finally exosomes loaded with TMPRSS2 are obtained. Example 8

[0109] This embodiment provides an exosome loaded with 4-1BBL, using the same polypeptide as in Example 1 as an exosome scaffold, and preparing the exosome loaded with 4-1BBL with reference to the preparation method of Example 1. The Cre recombinase in the expression frame as shown in SEQ ID NO: 2 is replaced with 4-1BBL as shown in SEQ ID NO: 47. In addition to redesigning the upstream primer (sequence as shown in SEQ ID NO: 48), the downstream primer (sequence as shown in SEQ ID NO: 49) and the template DNA (sequence as shown in SEQ ID NO: 50) of the synthetic PCR cloning step according to the adjusted expression frame (replacing the expression frame designed in Example 1), the rest is referred to Example 1, and finally the exosome loaded with 4-1BBL is obtained. Example 9

[0110] This example provides an exosome loaded with sgRNA, wherein the sequence of sgRNA is shown in SEQ ID NO: 51, Cas9 protein (sequence shown in SEQ ID NO: 20) is used as a protein linker, and the same polypeptide as in Example 1 is used as an exosome scaffold, and the Cas9 protein is fused to the N-terminus or C-terminus of the polypeptide as the scaffold to form a fusion protein modified exosome, and the sgRNA and Cas9 protein form an RNP complex, thereby obtaining exosomes loaded with sgRNA. Example 10

[0111] This example provides an exosome loaded with siRNA, wherein the sense strand sequence of the siRNA is shown in SEQ ID NO:52, the antisense strand sequence is shown in SEQ ID NO:53, and the AGO2 protein (sequence shown in SEQ ID NO:54) is used as a protein linker. The same polypeptide as in Example 1 is used as an exosome scaffold, and the AGO2 protein is fused to the N-terminus or C-terminus of the polypeptide as the scaffold to form a fusion protein modified exosome, and the siRNA and the AGO2 protein form an RNP complex, thereby obtaining exosomes loaded with siRNA. Embodiment 11

[0112] This example provides an exosome loaded with a small molecule compound, wherein the small molecule compound is rapamycin, and an FKBP12 protein (sequence shown in SEQ ID NO: 55) is used as a protein linker. The same polypeptide as in Example 1 is used as an exosome scaffold, and the FKBP12 protein is fused to the N-terminus or C-terminus of the polypeptide as a scaffold to form a fusion protein modified exosome, and rapamycin forms a complex with the FKBP12 protein, thereby obtaining exosomes loaded with the small molecule compound. Example 12

[0113] In this example, the mutant MGCGLNKKKKKKKKKK (shown in SEQ ID NO: 56, the second amino acid is myristoylated and the third amino acid is palmitoylated) of the polypeptide in Example 1 was used as an exosome scaffold protein, and exosomes loaded with Cre recombinant protease were prepared with reference to the preparation method of Example 1. The polypeptide with the amino acid sequence shown in SEQ ID NO: 3 in the expression frame was replaced with the polypeptide with the amino acid sequence shown in SEQ ID NO: 56, and the upstream primer (sequence shown in SEQ ID NO: 57), the downstream primer (sequence shown in SEQ ID NO: 58) and the template DNA (sequence shown in SEQ ID NO: 59) of the synthetic PCR cloning step were redesigned according to the adjusted expression frame. The rest was referred to Example 1, and finally exosomes loaded with Cre recombinant protease were obtained. Embodiment 13

[0114] The present embodiment provides a pharmaceutical composition for improving immune effects, which is prepared from the exosomes loaded with 4-1BBL of Example 3 and normal saline into an injection solution with a particle concentration of 1.0E12 particles / mL, and administered to experimental mice by intravenous injection. Since the exosomes loaded with 4-1BBL of Example 1 can effectively activate the immune response, promote T cell proliferation and activation, and stimulate monocytes to secrete inflammatory factors, the pharmaceutical composition of this embodiment can enhance the body's anti-tumor, anti-viral and other immune effects. Embodiment 14

[0115] This embodiment provides a pharmaceutical composition for preventing or treating novel coronavirus (SARS-CoV-2) infection, which is prepared from the exosomes loaded with TMPRSS2 of Example 4 and normal saline into an injection solution with a particle concentration of 1.0E12 particles / mL, and is administered to experimental mice by intravenous injection. TMPRSS2 is successfully delivered into the body and can bind to the spike protein of the novel coronavirus, thereby neutralizing the novel coronavirus and preventing the novel coronavirus from infecting upper respiratory tract cells and lung epithelial cells.

[0116] Exosome identification: The exosome resuspensions of the above examples and comparative examples were subjected to NTA analysis using a ZetaView instrument (Fuliu Bio Particle Metrix, catalog number N30E). The particle size distribution of the exosomes prepared in each example and comparative example is shown in Figures 1 to 12 The average particle size and median particle size are shown in Table 1.

[0117]

[0118] Table 1 shows that the particle size of the exosomes loaded with Cre recombinant protease in Example 1, Example 2, Comparative Example 1 and Comparative Example 2 is about 120~130nm, with no significant difference. The particle size of the exosomes loaded with Cas9 gene editing protein in Example 3, Example 4 and Comparative Example 3 is about 120~140nm, with no significant difference. The particle size of the exosomes loaded with cGAS pro-inflammatory protein in Example 5 and Example 6 is about 120~140nm, while the particle size of the exosomes loaded with cGAS pro-inflammatory protein in Comparative Example 4 is slightly larger, reaching about 150~160nm. The particle size of the exosomes loaded with TMPRSS2 in Example 7 and Comparative Example 5 is about 120~140nm, with no significant difference.

[0119] The structures of the exosomes prepared in the above examples and comparative examples were observed under a transmission electron microscope (TEM). Figure 13~Figure 24 As shown, the exosomes prepared in each embodiment and comparative example all have a cup-shaped or saucer-shaped typical exosome vesicle structure under an electron microscope, and there is no significant difference in morphology.

[0120] Analysis of exosome cargo enrichment efficiency: The exosomes loaded with Cre recombinant protease prepared in Example 1, Example 2 and Comparative Example 1 were loaded with the same amount (same number of exosome particles) for immunoblotting detection (western blot) to detect the expression level of Cre recombinant protease. The results are shown in Fig.25 .from Fig.25It can be seen that the brightness of the bands of Cre recombinant protease is from high to low: the exosomes prepared in Example 1, the exosomes prepared in Example 2, and the exosomes prepared in Comparative Example 1, indicating that the Cre recombinant protease enrichment degree of the exosomes prepared in Example 1 is the highest, the Cre recombinant protease enrichment degree of the exosomes prepared in Example 2 is the second highest, and the Cre recombinant protease enrichment degree of the exosomes prepared in Comparative Example 1 is the lowest.

[0121] The exosomes loaded with Cas9 gene editing protein prepared in Example 3, Example 4 and Comparative Example 3 were loaded with the same amount (same number of exosome particles) for immunoblotting detection (western blot) to detect the expression level of Cas9 gene editing protein. The results are shown in Fig. 27 .from Fig. 27 It can be seen that the brightness of the bands of the Cas9 gene editing protein is as follows from high to low: the exosomes prepared in Example 3, the exosomes prepared in Example 4, and the exosomes prepared in Comparative Example 3, indicating that the Cas9 gene editing protein enrichment level of the exosomes prepared in Example 3 is the highest, the Cas9 gene editing protein enrichment level of the exosomes prepared in Example 4 is the second highest, and the Cas9 gene editing protein enrichment level of the exosomes prepared in Comparative Example 3 is the lowest.

[0122] The exosomes loaded with cGAS pro-inflammatory protein prepared in Example 5, Example 6 and Comparative Example 4 were loaded with the same amount (same number of exosome particles) for immunoblotting (western blot) to detect the expression level of cGAS pro-inflammatory protein. The results are shown in Fig.29 .from Fig.29 It can be seen that the brightness of the bands of the Cas9 gene editing protein is from high to low as follows: the exosomes prepared in Example 5, the exosomes prepared in Example 6, and the exosomes prepared in Comparative Example 4, indicating that the exosomes prepared in Example 5 have the highest enrichment of cGAS pro-inflammatory protein, the exosomes prepared in Example 6 have the second highest enrichment of cGAS pro-inflammatory protein, and the exosomes prepared in Comparative Example 4 have the lowest enrichment of cGAS pro-inflammatory protein.

[0123] The same amount (same number of exosome particles) of the exosomes loaded with TMPRSS2 prepared in Example 7 and Comparative Example 5 were loaded for immunoblotting (western blot) to detect the expression level of TMPRSS2. The results are shown in Fig.31 .from Fig.31 It can be seen that the brightness of the band of the exosomes prepared in Example 7 is significantly higher than that of the exosomes prepared in Comparative Example 5, indicating that the enrichment degree of cGAS pro-inflammatory protein in the exosomes prepared in Example 7 is significantly higher than that in the exosomes prepared in Comparative Example 5.

[0124] Analysis of exosome cargo delivery efficiency: The exosomes loaded with Cre recombinant protease prepared in Example 1, Example 2 and Comparative Example 1 were added to the reporter cells for detecting Cre recombinant protease in equal amounts (same number of exosome particles). The genome of the reporter cells for detecting Cre recombinant protease contains both green fluorescent protein and red fluorescent protein, wherein the expression of red fluorescent protein is silent. Before the delivery of Cre recombinant protease, only green fluorescent protein is expressed. Cre recombinant protease-mediated recombination will activate the expression of red fluorescent protein. The reporter cells with successful delivery of Cre recombinant protease will express red fluorescent protein localized in the cell nucleus. Fig.26 It can be seen that the exosomes prepared in Example 1 and Example 2 have a good delivery efficiency for the Cre recombinant protease, among which the delivery efficiency of the exosomes prepared in Example 1 for the Cre recombinant protease basically reaches the Cre recombinant protease delivery efficiency equivalent to that of the exosomes prepared in Comparative Example 2, and the delivery effect of the exosomes prepared in Comparative Example 1 for the Cre recombinant protease is significantly lower than that of the exosomes prepared in Examples 1 and 2.

[0125] The exosomes loaded with Cas9 gene editing protein prepared in Example 3, Example 4 and Comparative Example 3 were added to the reporter cells for detecting Cas9 gene editing protein in equal amounts (same number of exosome particles). Under normal circumstances (when Cas9 gene editing protein is not delivered to the reporter cells), the reporter cells only express red fluorescent protein; while the reporter cells with successful delivery of Cas9 gene editing protein randomly correct the GFP gene with +1 or +2 frameshift mutation, thereby expressing green fluorescent protein. Fig. 27 It can be seen that the exosomes prepared in Example 3 and Example 4 have the highest delivery effect on Cas9 gene editing protein.

[0126] The exosomes loaded with cGAS pro-inflammatory protein prepared in Example 5, Example 6 and Comparative Example 4 were added to the reporter cells for detecting the STING pathway in equal amounts (same number of exosome particles). Under normal circumstances (when cGAS pro-inflammatory protein is not delivered to the reporter cells), the STING pathway is silent, so the reporter cells do not express luciferase and do not produce signals; however, in the reporter cells to which the cGAS pro-inflammatory protein is successfully delivered, the STING pathway is activated, so the reporter cells express luciferase and produce signals. Fig.30 It can be seen that after the exosomes prepared in Comparative Example 4, Example 6 and Example 5 were delivered, the STING activation multiples of the reporter cells increased successively, and the exosomes prepared in Example 5 had the highest delivery efficiency for cGAS pro-inflammatory protein.

[0127] The above embodiments and comparative examples show that the polypeptide derived from RFTN1 protein of the present invention can realize the function of exosome scaffold protein, enrich cargo into exosomes and successfully deliver it to cells, and the enrichment effect and delivery effect can reach a level comparable to that of the full-length RFTN1 protein and are superior to PTGFRN protein.

[0128] The present invention realizes the function of exosome scaffold protein with a polypeptide of significantly shorter length, and has at least the following advantages: (1) For some functional cargoes that are transmembrane proteins, there are currently few solutions in the field that can effectively achieve their enrichment in exosomes. By directly fusing the polypeptide exosome scaffold of the present invention to the end of the transmembrane protein, the transmembrane protein can be effectively enriched in the exosomes while having an ideal delivery efficiency, greatly expanding the application of exosomes as a drug delivery platform.

[0129] (2) Since the present invention uses a significantly shorter polypeptide scaffold to efficiently enrich the functional cargo of interest into exosomes, compared with existing scaffold protein technology, the present invention has significantly improved efficiency at the gene editing level. In most cases, shorter gene knock-in efficiency is higher and the editing difficulty at the cellular level is lower, which is conducive to the engineering transformation of cells.

[0130] (3) For some viral vectors, the length of the genome that can be packaged is relatively limited. For example, the current mainstream AAV vector generally has a packaging capacity of no more than 5kbp. The shorter the length of the scaffold, the longer the length of the drug protein that can be delivered. The present invention can significantly expand the delivery capacity and drug-making potential of vectors such as AAV.

[0131] (4) The present invention can avoid the problem that the complex folding conformation of the full-length scaffold protein affects the folding conformation and function of the functional cargo, and can also avoid the negative impact and adverse consequences on the physiology of the cell caused by the artificial modification of the full-length scaffold protein.

[0132] (5) The length of the fusion protein of the polypeptide scaffold and the functional cargo in the present invention is significantly shorter than that of the fusion protein of the full-length scaffold protein and the functional cargo, and the synthesis efficiency of the fusion protein is higher.

[0133] The above detailed description of the present invention is intended to enable those skilled in the art to understand the contents of the present invention and implement them, but it does not limit the protection scope of the present invention. The present invention is not limited to the above embodiments, and any equivalent changes or modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.

Claims

1. A drug delivery carrier, characterized in that The drug delivery carrier includes polypeptide-modified exosomes or fusion polypeptides or fusion protein-modified exosomes formed by the polypeptide and a linker, wherein the polypeptide includes a first fragment having n amino acids, the amino acid sequence of the first fragment has 80% to 100% identity with the first n amino acid sequences of the N-terminus of the RFTN1 protein, and the second amino acid of the first fragment is myristoylated glycine, and the third amino acid is palmitoylated cysteine, and n is 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or an integer between 16 and 50.

2. The drug delivery carrier according to claim 1, characterized in that The total length of the polypeptide is 9 to 10 amino acids or 11 to 100 amino acids.

3. The drug delivery carrier according to claim 1, characterized in that The first fragment has 11 to 20 amino acids, and the sequence is 80% to 100% identical to the first 11 to 20 amino acid sequences at the N-terminus of the RFTN1 protein.

4. The drug delivery carrier according to claim 3, characterized in that The first fragment has 15 or 16 amino acids, and the sequence is 80% to 100% identical to the first 15 or 16 amino acid sequences at the N-terminus of the RFTN1 protein.

5. The drug delivery carrier according to claim 1, characterized in that The polypeptide also includes a second fragment connected to the C-terminus of the first fragment, the second fragment has m amino acids, and its sequence is a fragment of the amino acid sequence of the RFTN1 protein or has 80% to 100% identity with the fragment of the amino acid sequence of the RFTN1 protein, and m is an integer greater than 2.

6. The drug delivery carrier according to claim 5, characterized in that The amino acid sequence of the second fragment has 80% to 100% identity with the m amino acid sequence starting from the n+1th amino acid at the N-terminus of the RFTN1 protein.

7. The drug delivery carrier according to claim 1, characterized in that The polypeptide further comprises a second fragment connected to the C-terminus of the first fragment, the second fragment has f amino acids, the f amino acids are positively charged amino acids, and f is an integer greater than 2.

8. The drug delivery carrier according to claim 7, characterized in that The first 6 amino acid sequences at the N-terminus of the first fragment are 100% identical to the first 6 amino acid sequences at the N-terminus of the RFTN1 protein.

9. The drug delivery carrier according to claim 7, characterized in that The first fragment has 6 to 20 amino acids, and the second fragment has 2 to 20 amino acids.

10. The drug delivery carrier according to claim 1, characterized in that The amino acid sequence of the polypeptide has 90% to 100% identity with the first 9 to 10 amino acid sequences or 11 to 100 amino acid sequences at the N-terminus of the RFTN1 protein.

11. The drug delivery carrier according to claim 1, characterized in that The amino acid sequence of the polypeptide has 90% to 100% identity with the first 9 to 10 amino acid sequences or 11 to 50 amino acid sequences at the N-terminus of the RFTN1 protein.

12. The drug delivery carrier according to any one of claims 1 to 11, characterized in that: The amino acid sequence of the RFTN1 protein is shown in any one of SEQ ID NO: 16 and SEQ ID NO: 60-68; and / or, The amino acid sequence of the first fragment has 80% to 100% identity with the first n amino acid sequences of the N-terminus of human RFTN1 protein, non-human mammalian RFTN1 protein, fish RFTN1 protein or avian RFTN1 protein, and the non-human mammalian RFTN1 protein, fish RFTN1 protein and avian RFTN1 protein are respectively selected from RFTN1 proteins whose first 6 amino acids at the N-terminus are the same as the first 6 amino acids at the N-terminus of human RFTN1 protein or whose amino acid is different in only one of the first 6 positions.

13. The drug delivery carrier according to claim 12, characterized in that: The one position is the 1st, 4th, 5th or 6th position from the N-terminus; and / or, the 2nd position of the amino acid sequence of the RFTN1 protein from the N-terminus is G, and the 3rd amino acid is C.

14. The drug delivery carrier according to claim 1, characterized in that The amino acid sequence of the polypeptide or the first fragment is: MGCGLNKLEK, MGCGLNKLEKR, MGCGLNKLEKRD, MGCGLNKLEKRDE, MGCGLNKLEKRDEK, MGCGLNKLEKRDEKR, MGCGLNKLEKRDEKRP, MGCGLNKLEKRDEKRPG, MGCGLNKLEKRDEKRPGN, MGCGLNKLEKRDEKRPGNI, MGCGLNKLEKRDEKRPGNIY, MGCGLNKLEKRDD, MGCGLNKLEKRDDK, MGCGLNKLEKRDDKR, MGCGLNKLEKRDDKRP, MGCGLNKLEKRDDKRPG, MGCGLNKLEKRDDKRPGN, MGCGLNKLEKRDDKRPGNI, MGCGLNKLEKRDDKRPGNIY, MGCSLNKLEK, MGCSLNKLEKR, MGCSLNKLEKRE, MGCSLNKLEKREK, MGCSLNKLEKREKR, MGCSLNKLEKREKRP, MGCSLNKLEKREKRPG, MGCSLNKLEKREKRPGN, MGCSLNKLEKREKRPGNI, MGCSLNKLEKREKRPGNIY, MGCRLNKLEK, MGCRLNKLEKR, MGCRLNKLEKRD, MGCRLNKLEKRDD, MGCRLNKLEKRDDR, MGCRLNKLEKRDDRR, MGCRLNKLEKRDDRRP, MGCRLNKLEKRDDRRPG, MGCRLNKLEKRDDRRPGN, MGCRLNKLEKRDDRRPGNI, MGCRLNKLEKRDDRRPGNIY, MGCGLNKLEKH, MGCGLNKLEKHD, MGCGLNKLEKHDE, MGCGLNKLEKHDEK, MGCGLNKLEKHDEKR, MGCGLNKLEKHDEKRP, MGCGLNKLEKHDEKRPG, MGCGLNKLEKHDEKRPGN, MGCGLNKLEKHDEKRPGNI, MGCGLNKLEKHDEKRPGNIY, MGCGLPKLEK, MGCGLPKLEKQ, MGCGLPKLEKQD, MGCGLPKLEKQDE, MGCGLPKLEKQDEN, MGCGLPKLEKQDENS, MGCGLPKLEKQDENSP, MGCGLPKLEKQDENSPG, MGCGLPKLEKQDENSPGK, MGCGLPKLEKQDENSPGKI,MGCGLPKLEKQDENSPGKIY。、 15. The drug delivery carrier according to claim 1, 2, 7 or 9, characterized in that: The first 6 amino acid sequences at the N-terminus of the polypeptide are 80% to 100% identical to the first 6 amino acid sequences at the N-terminus of the human RFTN1 protein, and the amino acid sequence of the polypeptide contains multiple consecutive positively charged amino acids.

16. The drug delivery carrier according to claim 15, characterized in that The amino acid sequence of the polypeptide is: MGCGLNKKKK, MGCGLNRRRR, MGCGLNHHHH, MGCGLNKKKKRRRR, MGCGLNRRRRKKKK, MGCGLNKKKKHHHH, MGCGLNKKKKKKKKK, MGCSLNKKKK, MGCSLNRRRR, MGCSLNHHHH, MGCSLNKKKKRRRR, MGCSLNRRRRKKKK, MGCCRLNKKKKHHHH, MGCRLNKKKKKKKKK, MGCRLNKKKK, MGCRLNRRRR, MGCRLNHHHH, MGCRLNKKKKRRRR, MGCRLNKKKKHHHH, MGCRLNKKKKKKKKKK.

17. An exosome loaded with cargo, wherein the cargo includes a pharmaceutically active molecule, characterized in that: The cargo-loaded exosomes include the drug delivery carrier according to any one of claims 1 to 16 and the pharmaceutically active molecule, wherein the pharmaceutically active molecule is connected to the polypeptide, or the pharmaceutically active molecule is connected to a fusion polypeptide or fusion protein formed by the polypeptide and a linker.

18. The cargo-loaded exosomes according to claim 17, characterized in that The pharmaceutically active molecules include one or more of protein molecules and fragments thereof, polypeptide molecules and fragments thereof, nucleic acids and fragments thereof or small molecule compounds.

19. The cargo-loaded exosomes according to claim 18, characterized in that The pharmaceutically active molecule is a cytokine receptor protein, a protein for gene editing, a pro-inflammatory cytokine or RNA.

20. The cargo-loaded exosomes according to claim 17, characterized in that The active drug molecule is Cre recombinase, Dre recombinase, Flp recombinase, cGAS, Cas protein, 4-1BBL, TMPRSS2, CD20, CD133, CCR4, CCR7, CCR8, CXCR4, CXCR5, GIPR, GPRC5D, NaPi2b, sgRNA, ASO, microRNA, mRNA or siRNA.

21. The cargo-carrying exosomes according to claim 17, characterized in that The pharmaceutically active molecule is a protein molecule and a fragment thereof or a polypeptide molecule and a fragment thereof, and the pharmaceutically active molecule is connected to the N-terminus and / or C-terminus of the polypeptide directly or through a polypeptide linker.

22. The cargo-loaded exosomes according to claim 17, characterized in that The pharmaceutically active molecule is a nucleic acid and a fragment thereof or a small molecule compound, the cargo-carrying exosomes include exosomes modified with a fusion polypeptide or a fusion protein formed by the polypeptide and a linker, and the pharmaceutically active molecule and the linker are combined to form a complex.

23. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the drug delivery vector according to any one of claims 1 to 16 or the cargo-loaded exosomes according to any one of claims 17 to 22, and the pharmaceutical composition may optionally comprise a pharmaceutically acceptable excipient.

24. The pharmaceutical composition according to claim 23, characterized in that The pharmaceutical composition is in the form of tablets, granules, pills, capsules, emulsions, pastes, gels, suspensions, solutions, powders, transdermal patches, sprays, suppositories or implants.

25. The method for preparing a drug delivery carrier according to any one of claims 1 to 16, characterized in that: The drug delivery carrier is separated from the cell culture fluid of the recombinant cell, wherein the recombinant cell contains the polypeptide or a fusion polypeptide or fusion protein formed by the polypeptide and a linker.

26. The method for preparing a drug delivery carrier according to claim 25, characterized in that: The cell culture medium used to culture the recombinant cells is a serum-free medium; And / or, the separation is carried out by centrifugation, first centrifuging the cell culture fluid of the recombinant cells at a centrifugal force of less than 1000g, collecting the supernatant, and then centrifuging the supernatant at a centrifugal force of 100000g~200000g to collect the precipitate, which is the drug delivery vector.

27. A kit, characterized in that The kit comprises the drug delivery vector according to any one of claims 1 to 16, or the cargo-loaded exosomes according to any one of claims 17 to 22, or the pharmaceutical composition according to claim 23 or 24.

28. Use of a polypeptide or a fusion polypeptide or fusion protein formed by the polypeptide and a linker as an exosome scaffold to enrich cargo into exosomes, characterized in that: The polypeptide is the polypeptide according to any one of claims 1 to 16.

Citation Information

Patent Citations

  • Human cancer suppressor gene, protein encoded therein, expression vector containing same

    CN101128481A

  • Preparation and application of engineered exosome for efficiently and controllably packaging endogenous nucleic acid

    CN110885789A

  • Double-layer membrane vesicle containing modified protein for drug delivery as well as preparation method and application of double-layer membrane vesicle

    CN116271102A

  • Exosome scaffold protein especially suitable for internally loading effective goods and application thereof

    CN118460477A

  • Exosome-enriched polypeptide, genetically engineered exosome thereof, and preparation method and application of exosome-enriched polypeptide and genetically engineered exosome

    CN118772248A

Cited By

  • NPL three-modification tag and application thereof in improving exosome secretion level of target protein

    CN121574194A

  • Construction and use of polypeptide-based coacervate carrier

    WO2026214739A1